I would have found these SVR4 numbers for ABT-493/ABT-530 in GT3 patients surprisingly strong if not for the tip-off from ABBV’s Morgan Stanley webcast in mid September (#msg-117120410).
Those are two distinct points. V-Pak may be obsolete in two years if ABT-493/ABT-530 is non-inferior to V-Pak in GT1 efficacy; however, this doesn’t imply that future HCV regimens must include a nuke to be competitive. (ABT-493/ABT-530 does not contain a nuke.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.